Foundry
#8 in Wetenschop- & Bio-KIPathos Ai · siet Nicht belegt (Plattform in Pathos-Pressemitteilungen seit mindestens Mai 2026 erwähnt) · 2× · tolest 27. Okt. 2026
38
Momentum
Foundry is the proprietary AI platform of the New York-based drug development company Pathos AI, focused on oncology. According to the company, Foundry uses thousands of specialized AI agents that analyze clinical, genomic and competitive data to prioritize drug candidates and support development decisions. It forms part of the PathOS architecture together with Scout and Sprint.
Momentum-Verloop
30.07.28.10.
Features
| Deployment Model | Not publicly documented; access via strategic partnerships (e.g., BMS) |
| Use Case Scope | Oncology drug development: analysis of trial/research data, candidate selection, trial design |
| Integrations | Oncology Foundation Model built in partnership with Tempus and AstraZeneca; connected to Pathos wetlab |
| License | Commercial partnerships/licensing to pharma (e.g., BMS: non-exclusive access to Foundry as part of Series E financing) |
| Platform | Part of the PathOS platform; shared AI core for Scout and Sprint, connected to a lab-in-the-loop validation system |